Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for China Shineway Pharmaceutical Group's Price-to-Tangible-Book or its related term are showing as below:
CSWYY'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.66 Med: 0.93 Max: 1.27
Current: 0.72
During the past 13 years, China Shineway Pharmaceutical Group's highest Price to Tangible Book Ratio was 1.27. The lowest was 0.66. And the median was 0.93.
CSWYY's Price-to-Tangible-Book is ranked better than 88.53% of 837
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs CSWYY: 0.72
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
China Shineway Pharmaceutical Group Price-to-Tangible-Book Related Terms
China Shineway Pharmaceutical Group Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group Price-to-Tangible-Book Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
China Shineway Pharmaceutical Group (CSWYY) has a Price-to-Tangible-Book of 0.65 as of Sep. 06, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on China Shineway Pharmaceutical Group and its competitors. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #96 out of 837 companies in the Drug Manufacturers industry, placing it in the top 11.5%.
Is China Shineway Pharmaceutical Group's Price-to-Tangible-Book too high?
China Shineway Pharmaceutical Group's current Price-to-Tangible-Book is 0.65. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.30. China Shineway Pharmaceutical Group's value of 0.65 is 71.7% below this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #96 out of 837 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's Price-to-Tangible-Book compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #96 out of 837 companies for Price-to-Tangible-Book. This places China Shineway Pharmaceutical Group in the top 12% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 2.30. China Shineway Pharmaceutical Group's value of 0.65 is 71.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.30, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current Price-to-Tangible-Book of 0.65 is 71.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current Price-to-Tangible-Book is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current Price-to-Tangible-Book of 0.65. The stock's GF Value™ is $13.24, compared to a current price of $19.25 — trading 45.4% above its estimated fair value. The current Price-to-Tangible-Book is 0.65 and 71.7% below the Drug Manufacturers industry median of 2.30. China Shineway Pharmaceutical Group's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current Price-to-Tangible-Book is 0.65 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 45.4% above its estimated GF Value™ of $13.24.
Key valuation signals for CSWYY:
Price-to-Tangible-Book: 0.65
GF Value™: $13.24 vs. price of $19.25 (45.4% above fair value)
Industry Position: 71.7% below the Drug Manufacturers median (#96 of 837)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
83GF Score
Get the complete analysis for CSWYY
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
